Syncrosome provides a wide range of screening models in respiratory preclinical disease with a focus expertise on inflammatory diseases including Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cough. Our disease models (ferrets, rats or mice depending on the pathology) are fitted for testing disease-modifying drug or compounds acting on symptomatic effects. Following your needs, it is possible to perform classical, Intranasal or Intratracheal (powder and liquid) administration or to use a nebulizer.
We perform symptomatic read out such as whole body plethysmography (tidal volume, respiratory rate, expiration time, respiratory flows, PenH, etc…) and special software analysis. We associated to these parameters the study of specific biomarkers by Histology and/or ELISA (Cellular biomarkers, cytokines). This combination of different techniques makes us the ideal partners for a quick answer about the potential efficacy of your compounds on respiratory pathologies with high content studies.
Our respiratory department also has the knowledge and skills to evaluate security aspects in parallel with efficacy studies on the same species and at the same time.
We offer you the possibility to screen your compound with simplified protocols, allowing you to save time in the development of your potential new drug.